Reaching optimal levels for cholesterol and high blood pressure in people who've had a stroke adds up to prevent a second stroke or heart attack, according to a study presented as part of the Late-breaking Science Program at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 - May 2, 2009.
Researchers looked at four risk factors for stroke: high LDL cholesterol, low HDL cholesterol, high triglycerides, and high blood pressure. They found that for each risk factor that is controlled at the optimal level, the risk of stroke and other major cardiovascular problems goes down.
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study involved 4,731 people who had a recent stroke or transient ischemic attack, or mini stroke. Half received the cholesterol-lowering drug atorvastatin, and half received a placebo. The participants were followed for an average of 4.9 years.
People who reached optimal levels in all four risk factors were 65 percent less likely to have another stroke as people who did not reach optimal levels on any of the risk factors. Those who reached the optimal level on three risk factors were 38 percent less likely to have another stroke, and those who reached the optimal level on two risk factors were 22 percent less likely to have another stroke. Those who reached the optimal level on only one risk factor were only two percent less likely to have another stroke than people who did not meet any of the optimal levels.
"These results show that there is a cumulative effect to lowering cholesterol and blood pressure," said study author Pierre Amarenco, MD, of Denis Diderot University and Medical School in Paris, France, and a Fellow of the American Academy of Neurology. "People need to work with their doctors to reach the optimal level on all of these risk factors."
Amarenco said prior to this study researchers knew that lowering cholesterol and blood pressure was helpful overall in preventing stroke, but did not know whether one risk factor played a stronger role than another.
The optimal levels were defined as LDL "bad" cholesterol of lower than 70, HDL "good" cholesterol of higher than 50, triglycerides less than 150, and blood pressure less than 120/80.
The study was supported by Pfizer Inc.
вторник, 9 августа 2011 г.
суббота, 6 августа 2011 г.
New Data Submitted To FDA Supporting Use Of Omacor With A Statin To Reduce High Triglycerides
Reliant Pharmaceuticals today announced a submission to the U.S. Food and Drug Administration (FDA) to seek approval for the expanded use of Omacor (omega-3-acid ethyl esters) as an adjunct to diet and statin therapy in adults whose triglyceride levels are high (200-499 mg/dL).? As part of this filing, Reliant submitted new data from the recently completed Combination of Omacor and Simvastatin (COMBOS) trial that evaluated the efficacy and safety of Omacor as an adjunct to diet and simvastatin therapy for the treatment of high triglycerides. ? COMBOS is a randomized, double-blind, placebo-controlled, parallel-group study including 254 patients.
"Currently, Omacor may help up to 5 million Americans whose triglyceride levels are very high," said Steven Ketchum, Ph.D., Senior Vice President, Research and Development, Reliant Pharmaceuticals.? "There are an estimated 27 million Americans who struggle to control high triglycerides.? By seeking this expanded indication, Omacor may serve as a safe, new treatment option for adults whose triglyceride levels remain high in spite of statin therapy."
Omacor is the first and only FDA-approved, prescription omega-3 fatty acid product, and has been proven safe and effective in clinical studies as an adjunct to diet to reduce very high triglycerides (?‰?500 mg/dL) in adult patients.? Very high triglycerides (?‰?500 mg/dL) impact 4-5 million people in the United States.? Omacor contains the key omega-3 components, eicosapentaenoic acid (465 mg) and docosahexaenoic acid (375 mg), to reduce very high triglycerides, and is naturally derived through a unique, patented process that consistently creates a highly concentrated and purified prescription medicine.
When Omacor was granted FDA approval in 2004, the FDA issued an approvable letter for the use of Omacor as an adjunct to diet and statin therapy to reduce high triglyceride levels (200-499 mg/dL) in adult patients.? Submission of this response is intended to demonstrate the safety and efficacy of the expanded use of Omacor before FDA approval is granted.
?
About High Triglycerides
Like the other types of cholesterol, triglycerides are fats (lipids) that, in balanced and moderate amounts, perform significant and important functions in the body. Triglycerides are derived from either fats ingested from food or other energy sources like carbohydrates in the body.? After a meal, the calories that are not used immediately by tissues are then converted into triglycerides and distributed among fat cells to be stored.? Hormones found in the body then regulate the release of triglycerides from fat tissue so they may be used for energy between meals. ? According to the American Heart Association (AHA), a normal level of triglycerides is below 150 mg/dL.? Like cholesterol, triglyceride levels can be detected by a blood test.? A high triglyceride level causes a condition known as hypertriglyceridemia, which is linked to the occurrence of heart disease in some people.
?
Important Omacor Safety Information
Omacor is used along with a low-fat and low-cholesterol diet to lower very high triglycerides (fats) in adults. Before taking Omacor, your healthcare provider should help you try to control your very high triglyceride levels by: losing weight if you are overweight, increasing physical exercise, lowering alcohol use, treating diseases such as diabetes and low thyroid hormone levels (hypothyroidism), and adjusting other medications that may raise triglyceride levels such as certain blood pressure medications and estrogens.
?
Omacor should be used with caution in people allergic to fish.? Treatment to reduce very high triglyceride levels may result in elevations in LDL-C and non-HDL-C in some individuals.? The effect of Omacor on cardiovascular morbidity and mortality in patients with very high triglyceride levels has not been determined.
?
Tell your healthcare provider about all your medical conditions, including if you have liver problems, are pregnant, are trying to become pregnant or are breast-feeding.? Tell your healthcare provider if you take blood thinners.? If you take both Omacor and a blood thinner, your healthcare provider should monitor your clinical response.
?
The most common side effects observed in Omacor clinical trials were belching, infection, flu symptoms, upset stomach, rash and change in your sense of taste.?
?
For more detailed information about Omacor, ask your healthcare provider or go to omacorrx.
?
About Reliant Pharmaceuticals
Reliant Pharmaceuticals is a pharmaceutical company with integrated sales, marketing and development expertise that markets a portfolio of branded cardiovascular pharmaceutical products.? Reliant focuses on marketing promotionally sensitive pharmaceutical products to the high prescribing primary care, cardiovascular and specialist physician markets in the United States.? Reliant also acquires rights to and develops product candidates in mid- to late-stage clinical development.? Reliant's sales force infrastructure is comprised of approximately 825 sales professionals nationwide.
?
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.
? To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.
"Currently, Omacor may help up to 5 million Americans whose triglyceride levels are very high," said Steven Ketchum, Ph.D., Senior Vice President, Research and Development, Reliant Pharmaceuticals.? "There are an estimated 27 million Americans who struggle to control high triglycerides.? By seeking this expanded indication, Omacor may serve as a safe, new treatment option for adults whose triglyceride levels remain high in spite of statin therapy."
Omacor is the first and only FDA-approved, prescription omega-3 fatty acid product, and has been proven safe and effective in clinical studies as an adjunct to diet to reduce very high triglycerides (?‰?500 mg/dL) in adult patients.? Very high triglycerides (?‰?500 mg/dL) impact 4-5 million people in the United States.? Omacor contains the key omega-3 components, eicosapentaenoic acid (465 mg) and docosahexaenoic acid (375 mg), to reduce very high triglycerides, and is naturally derived through a unique, patented process that consistently creates a highly concentrated and purified prescription medicine.
When Omacor was granted FDA approval in 2004, the FDA issued an approvable letter for the use of Omacor as an adjunct to diet and statin therapy to reduce high triglyceride levels (200-499 mg/dL) in adult patients.? Submission of this response is intended to demonstrate the safety and efficacy of the expanded use of Omacor before FDA approval is granted.
?
About High Triglycerides
Like the other types of cholesterol, triglycerides are fats (lipids) that, in balanced and moderate amounts, perform significant and important functions in the body. Triglycerides are derived from either fats ingested from food or other energy sources like carbohydrates in the body.? After a meal, the calories that are not used immediately by tissues are then converted into triglycerides and distributed among fat cells to be stored.? Hormones found in the body then regulate the release of triglycerides from fat tissue so they may be used for energy between meals. ? According to the American Heart Association (AHA), a normal level of triglycerides is below 150 mg/dL.? Like cholesterol, triglyceride levels can be detected by a blood test.? A high triglyceride level causes a condition known as hypertriglyceridemia, which is linked to the occurrence of heart disease in some people.
?
Important Omacor Safety Information
Omacor is used along with a low-fat and low-cholesterol diet to lower very high triglycerides (fats) in adults. Before taking Omacor, your healthcare provider should help you try to control your very high triglyceride levels by: losing weight if you are overweight, increasing physical exercise, lowering alcohol use, treating diseases such as diabetes and low thyroid hormone levels (hypothyroidism), and adjusting other medications that may raise triglyceride levels such as certain blood pressure medications and estrogens.
?
Omacor should be used with caution in people allergic to fish.? Treatment to reduce very high triglyceride levels may result in elevations in LDL-C and non-HDL-C in some individuals.? The effect of Omacor on cardiovascular morbidity and mortality in patients with very high triglyceride levels has not been determined.
?
Tell your healthcare provider about all your medical conditions, including if you have liver problems, are pregnant, are trying to become pregnant or are breast-feeding.? Tell your healthcare provider if you take blood thinners.? If you take both Omacor and a blood thinner, your healthcare provider should monitor your clinical response.
?
The most common side effects observed in Omacor clinical trials were belching, infection, flu symptoms, upset stomach, rash and change in your sense of taste.?
?
For more detailed information about Omacor, ask your healthcare provider or go to omacorrx.
?
About Reliant Pharmaceuticals
Reliant Pharmaceuticals is a pharmaceutical company with integrated sales, marketing and development expertise that markets a portfolio of branded cardiovascular pharmaceutical products.? Reliant focuses on marketing promotionally sensitive pharmaceutical products to the high prescribing primary care, cardiovascular and specialist physician markets in the United States.? Reliant also acquires rights to and develops product candidates in mid- to late-stage clinical development.? Reliant's sales force infrastructure is comprised of approximately 825 sales professionals nationwide.
?
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.
? To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.
среда, 3 августа 2011 г.
Livazo(R) (Pitavastatin), A Statin With Beneficial Effects On Lipid Fractions Associated With Heart Disease, Launches In Lebanon
Kowa Pharmaceutical Europe welcomes the first regional launch of its
statin, Livazo (pitavastatin) in Lebanon, where it will be marketed by
Beirut-based Algorithm, under an exclusive license.
Aimed at patients with primary hyperlipidemia and / or mixed
dyslipidemia,(1) Lebanon will be the first market for Livazo outside the Far
East and the USA. Algorithm will launch Livazo in the rest of the Middle East
and North Africa from 2012 onwards.
Livazo is a potent statin that combines effective control on
LDL-cholesterol (LDL-C) and triglycerides (TG), long-term incremental
HDL-cholesterol (HDL-C) increase and, due to its novel structure, is less
likely to have drug-drug interactions.(2) Its effectiveness has been
demonstrated in several Phase III clinical studies:
- Livazo safely and effectively reduced LDL-C and achieved European
Atherosclerosis Society (EAS) guideline targets in the majority of
patients with primary hyperlipidemia or mixed dyslipidemia, similar
to reductions seen with atorvastatin(3) and simvastatin(4)
- Livazo 2 mg and 4 mg demonstrated comparable efficacy to commonly
prescribed statins with 2 mg Livazo demonstrating statistically
significant superior efficacy compared with simvastatin 20 mg in
lowering LDL-C, non high-density lipoprotein cholesterol (non-HDL-C)
and total cholesterol (TC)(4)
- Livazo effectively reduced LDL-C in the elderly(5) and also improved
LDL-C and other parameters of lipid metabolism in patients at higher
cardiovascular risk(2)
- Livazo was superior to pravastatin in improving LDL-C in elderly
patients (65 years)(5)
- Livazo demonstrated a gradual and sustained increase in HDL-C over the
long-term, supported by data from a 52 week extension study(6)
"We welcome innovative treatments such as Livazo, which not only lowers
LDL-C effectively but also addresses HDL residual risk and so has the
potential to increase the proportion of patients achieving treatment
targets," said Professor Ibrahim Salti, Professor of Medicine and Head of the
Division of Endocrinology and Metabolism at the American University of Beirut
in Lebanon. "Pitavastatin has shown good efficacy in metabolic syndrome
patients without effect on HbA1C levels, as well as in elderly patients. The
low drug-drug interaction makes it an attractive option for clinically
complex patients on multiple medications."
High cholesterol levels are a major risk factor for heart disease, the
number one cause of death globally.(7) In Lebanon, about one sixth of all
adults has high blood cholesterol, but only two fifths of these receive
medical treatment for it.(8)
The overall safety and tolerability of pitavastatin are consistent with
other commonly prescribed statins. In Phase III studies comparing
pitavastatin with atorvastatin(3), simvastatin(4) and pravastatin(5), the
overall safety profile of pitavastatin was demonstrated, with low incidences
of adverse events. All three doses of pitavastatin (1, 2 and 4 mg)
demonstrated a comparable safety profile to 10, 20 and 40 mg of
pravastatin(5), which is considered to be the statin least likely to cause
adverse drug reactions or drug-drug interactions. Additionally, pitavastatin
has demonstrated a long-term safety profile (to 52 weeks),(6) comparable to
that of simvastatin or atorvastatin.(9,10)
Drummond Paris, President of Kowa Research Europe, said: "The launch of
Livazo in Lebanon represents a milestone for Kowa as our first product in
this region. It will be the first of many launches in Europe, the Middle East
and North Africa during 2011. We are keen to offer the benefits of Livazo to
patients across the globe."
References
1. Livazo Summary of Product Characteristics
2. Ose L. Pitavastatin: finding its place in therapy. Ther Adv Chronic
Dis. 2011. Published online before print. January 26, 2011, doi:
10.1177/2040622310389227
3. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin
compared with atorvastatin in primary hypercholesterolemia or
combined dyslipidemia. Clin. Lipidol. 2009;4:291-302
4. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin
with simvastatin in primary hypercholesterolaemia or combined
dyslipidaemia. Curr Med Res Opin 2009;25: 2755-64
5. Stender S, Hounslow N. Robust efficacy of pitavastatin and comparable
safety to pravastatin. Atherosclerosis Suppl. 2009; 10:e945
6. Ose L, Budinski D, Hounslow N, Arneson V: Long-term treatment with
pitavastatin is effective and well tolerated by patients with primary
hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010;
202-208
7. World Health Organization. Cardiovascular diseases fact sheet.
Accessed on 14 February, 2011.
See here.
8. Rady, A. Is lifestyle affecting the risk of non-communicable diseases
in Lebanon? Human & Health 2010;13:15-17
9. Data on file (study 309)
10. Data on file (study 310)
About Livazo
Pitavastatin (a statin) is a fully synthetic and highly potent inhibitor
of HMG-CoA reductase used for primary hypercholesterolemia and combined
dyslipidemia. Pitavastatin has a unique cyclopropyl group on the base
structure common to the statin class. Since its 2003 launch in Japan,
pitavastatin has accumulated millions of patient-years of exposure. Many of
these patients have co-morbidities and are taking multiple medications. Kowa
received FDA approval of pitavastatin (Livalo(R)) for the treatment of
primary hyperlipidemia or mixed dyslipidemia in August 2009 and it was
launched in the U.S. in June 2010. Additionally, Kowa filed in Europe in
August 2008 using the decentralised authorisation procedure and received
regulatory approval in mid 2010. In much of Europe, pitavastatin will be
marketed by Recordati. Pitavastatin will be available in three dosage
strengths (1 mg, 2 mg and 4 mg).
*1. Co-marketing by the two companies under one brand name, Livalo. The
annual sales of Livalo tablets in Japan reached $520 million in 2010.
*2 Kowa (Shanghai) Pharma Consulting Co. Ltd., a wholly-owned subsidiary
of Kowa, is obtaining and providing information to physicians and hospitals
in China to ensure proper use of pitavastatin.
*3 In the United States, Kowa Pharmaceuticals America, Inc. (Headquarters
in Alabama, US), a wholly-owned subsidiary of Kowa, sell and market
pitavastatin with a co-promotion partner, Eli Lilly (Headquarters in Indiana,
US).
*4 In Europe, pitavastatin will be distributed by Kowa Pharmaceutical
Europe Co. Ltd. (Headquarters in Wokingham, UK), a wholly-owned subsidiary of
Kowa, and Recordati (Headquarters in Milan, Italy), a partner distributor.
About Algorithm
Algorithm, pharmaceutical manufacturer based in Lebanon, aims
at being the trusted regional partner to medical and patient communities and
is committed to delivering quality care in pharmaceutical therapies. It
operates in the Middle East and North Africa region with a product portfolio
consisting of innovative products as well as differentiated generics,
focusing mainly on the following therapeutic areas: cardiology,
endocrinology, neurology, gynaecology and urology. Algorithm has built
partnerships with many international companies, amongst which is Kowa.
statin, Livazo (pitavastatin) in Lebanon, where it will be marketed by
Beirut-based Algorithm, under an exclusive license.
Aimed at patients with primary hyperlipidemia and / or mixed
dyslipidemia,(1) Lebanon will be the first market for Livazo outside the Far
East and the USA. Algorithm will launch Livazo in the rest of the Middle East
and North Africa from 2012 onwards.
Livazo is a potent statin that combines effective control on
LDL-cholesterol (LDL-C) and triglycerides (TG), long-term incremental
HDL-cholesterol (HDL-C) increase and, due to its novel structure, is less
likely to have drug-drug interactions.(2) Its effectiveness has been
demonstrated in several Phase III clinical studies:
- Livazo safely and effectively reduced LDL-C and achieved European
Atherosclerosis Society (EAS) guideline targets in the majority of
patients with primary hyperlipidemia or mixed dyslipidemia, similar
to reductions seen with atorvastatin(3) and simvastatin(4)
- Livazo 2 mg and 4 mg demonstrated comparable efficacy to commonly
prescribed statins with 2 mg Livazo demonstrating statistically
significant superior efficacy compared with simvastatin 20 mg in
lowering LDL-C, non high-density lipoprotein cholesterol (non-HDL-C)
and total cholesterol (TC)(4)
- Livazo effectively reduced LDL-C in the elderly(5) and also improved
LDL-C and other parameters of lipid metabolism in patients at higher
cardiovascular risk(2)
- Livazo was superior to pravastatin in improving LDL-C in elderly
patients (65 years)(5)
- Livazo demonstrated a gradual and sustained increase in HDL-C over the
long-term, supported by data from a 52 week extension study(6)
"We welcome innovative treatments such as Livazo, which not only lowers
LDL-C effectively but also addresses HDL residual risk and so has the
potential to increase the proportion of patients achieving treatment
targets," said Professor Ibrahim Salti, Professor of Medicine and Head of the
Division of Endocrinology and Metabolism at the American University of Beirut
in Lebanon. "Pitavastatin has shown good efficacy in metabolic syndrome
patients without effect on HbA1C levels, as well as in elderly patients. The
low drug-drug interaction makes it an attractive option for clinically
complex patients on multiple medications."
High cholesterol levels are a major risk factor for heart disease, the
number one cause of death globally.(7) In Lebanon, about one sixth of all
adults has high blood cholesterol, but only two fifths of these receive
medical treatment for it.(8)
The overall safety and tolerability of pitavastatin are consistent with
other commonly prescribed statins. In Phase III studies comparing
pitavastatin with atorvastatin(3), simvastatin(4) and pravastatin(5), the
overall safety profile of pitavastatin was demonstrated, with low incidences
of adverse events. All three doses of pitavastatin (1, 2 and 4 mg)
demonstrated a comparable safety profile to 10, 20 and 40 mg of
pravastatin(5), which is considered to be the statin least likely to cause
adverse drug reactions or drug-drug interactions. Additionally, pitavastatin
has demonstrated a long-term safety profile (to 52 weeks),(6) comparable to
that of simvastatin or atorvastatin.(9,10)
Drummond Paris, President of Kowa Research Europe, said: "The launch of
Livazo in Lebanon represents a milestone for Kowa as our first product in
this region. It will be the first of many launches in Europe, the Middle East
and North Africa during 2011. We are keen to offer the benefits of Livazo to
patients across the globe."
References
1. Livazo Summary of Product Characteristics
2. Ose L. Pitavastatin: finding its place in therapy. Ther Adv Chronic
Dis. 2011. Published online before print. January 26, 2011, doi:
10.1177/2040622310389227
3. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin
compared with atorvastatin in primary hypercholesterolemia or
combined dyslipidemia. Clin. Lipidol. 2009;4:291-302
4. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin
with simvastatin in primary hypercholesterolaemia or combined
dyslipidaemia. Curr Med Res Opin 2009;25: 2755-64
5. Stender S, Hounslow N. Robust efficacy of pitavastatin and comparable
safety to pravastatin. Atherosclerosis Suppl. 2009; 10:e945
6. Ose L, Budinski D, Hounslow N, Arneson V: Long-term treatment with
pitavastatin is effective and well tolerated by patients with primary
hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010;
202-208
7. World Health Organization. Cardiovascular diseases fact sheet.
Accessed on 14 February, 2011.
See here.
8. Rady, A. Is lifestyle affecting the risk of non-communicable diseases
in Lebanon? Human & Health 2010;13:15-17
9. Data on file (study 309)
10. Data on file (study 310)
About Livazo
Pitavastatin (a statin) is a fully synthetic and highly potent inhibitor
of HMG-CoA reductase used for primary hypercholesterolemia and combined
dyslipidemia. Pitavastatin has a unique cyclopropyl group on the base
structure common to the statin class. Since its 2003 launch in Japan,
pitavastatin has accumulated millions of patient-years of exposure. Many of
these patients have co-morbidities and are taking multiple medications. Kowa
received FDA approval of pitavastatin (Livalo(R)) for the treatment of
primary hyperlipidemia or mixed dyslipidemia in August 2009 and it was
launched in the U.S. in June 2010. Additionally, Kowa filed in Europe in
August 2008 using the decentralised authorisation procedure and received
regulatory approval in mid 2010. In much of Europe, pitavastatin will be
marketed by Recordati. Pitavastatin will be available in three dosage
strengths (1 mg, 2 mg and 4 mg).
*1. Co-marketing by the two companies under one brand name, Livalo. The
annual sales of Livalo tablets in Japan reached $520 million in 2010.
*2 Kowa (Shanghai) Pharma Consulting Co. Ltd., a wholly-owned subsidiary
of Kowa, is obtaining and providing information to physicians and hospitals
in China to ensure proper use of pitavastatin.
*3 In the United States, Kowa Pharmaceuticals America, Inc. (Headquarters
in Alabama, US), a wholly-owned subsidiary of Kowa, sell and market
pitavastatin with a co-promotion partner, Eli Lilly (Headquarters in Indiana,
US).
*4 In Europe, pitavastatin will be distributed by Kowa Pharmaceutical
Europe Co. Ltd. (Headquarters in Wokingham, UK), a wholly-owned subsidiary of
Kowa, and Recordati (Headquarters in Milan, Italy), a partner distributor.
About Algorithm
Algorithm, pharmaceutical manufacturer based in Lebanon, aims
at being the trusted regional partner to medical and patient communities and
is committed to delivering quality care in pharmaceutical therapies. It
operates in the Middle East and North Africa region with a product portfolio
consisting of innovative products as well as differentiated generics,
focusing mainly on the following therapeutic areas: cardiology,
endocrinology, neurology, gynaecology and urology. Algorithm has built
partnerships with many international companies, amongst which is Kowa.
воскресенье, 31 июля 2011 г.
Patients With High CRP And Normal LDL Have Long-Term Risk For Heart Disease, Stroke And Death
New research shows a long-term benefit in screening people for CRP, a marker for inflammation, even if they have normal levels of bad cholesterol, because of increased long-term risk for heart attack, stroke and death.
These findings, which will be published online today in the Journal of the American College of Cardiology (JACC), demonstrate that a very simple screening, age plus CRP, can identify individuals who may benefit from statin therapy.
"This study builds on results from the landmark JUPITER trial, which showed that statins can prevent heart disease in people with normal LDL-c, or bad cholesterol, and an increased level of CRP," said Dr. Christie Ballantyne, director of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart & Vascular Center and last author on the study. "We have demonstrated that the cardiovascular disease event rates persist over time, validating that the risks identified in the JUPITER trial persist for nearly seven years."
Questions remained after the JUPITER results were announced in 2008, including whether the observed cardiovascular disease (CVD) event rates would persist with time, because JUPITER was stopped early at two years median follow-up.
"The new study analyzed patients' risk over an average of seven years to determine that CRP is, in fact, a long-term indicator of cardiovascular risk," said Ballantyne, who is also professor of medicine at Baylor College of Medicine. "This is important because approximately one in five men over 50 and women over 60 has a similar profile of increased CRP but normal LDL."
About the study
Methods: After stratification into four groups based on LDL cholesterol (LDL-C) and high-sensitivity CRP (hs-CRP) levels, with cutoffs at 130 mg/dL and 2.0 mg/L respectively, incident CVD events were examined (mean follow-up 6.9 years) and compared.
Results: Of 8,907 age-eligible participants, 18.2 percent (n=1,621) were "JUPITER-eligible" (hs-CRP ?‰?2.0 mg/L, LDL-C
These findings, which will be published online today in the Journal of the American College of Cardiology (JACC), demonstrate that a very simple screening, age plus CRP, can identify individuals who may benefit from statin therapy.
"This study builds on results from the landmark JUPITER trial, which showed that statins can prevent heart disease in people with normal LDL-c, or bad cholesterol, and an increased level of CRP," said Dr. Christie Ballantyne, director of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart & Vascular Center and last author on the study. "We have demonstrated that the cardiovascular disease event rates persist over time, validating that the risks identified in the JUPITER trial persist for nearly seven years."
Questions remained after the JUPITER results were announced in 2008, including whether the observed cardiovascular disease (CVD) event rates would persist with time, because JUPITER was stopped early at two years median follow-up.
"The new study analyzed patients' risk over an average of seven years to determine that CRP is, in fact, a long-term indicator of cardiovascular risk," said Ballantyne, who is also professor of medicine at Baylor College of Medicine. "This is important because approximately one in five men over 50 and women over 60 has a similar profile of increased CRP but normal LDL."
About the study
Methods: After stratification into four groups based on LDL cholesterol (LDL-C) and high-sensitivity CRP (hs-CRP) levels, with cutoffs at 130 mg/dL and 2.0 mg/L respectively, incident CVD events were examined (mean follow-up 6.9 years) and compared.
Results: Of 8,907 age-eligible participants, 18.2 percent (n=1,621) were "JUPITER-eligible" (hs-CRP ?‰?2.0 mg/L, LDL-C
четверг, 28 июля 2011 г.
Statins May Lessen Brain Function, Says ISU Researcher
Research by an Iowa State University scientist suggests that cholesterol-reducing drugs known as statins may lessen brain function.
Yeon-Kyun Shin, a biophysics professor in the department of biochemistry, biophysics and molecular biology, says the results of his study show that drugs that inhibit the liver from making cholesterol may also keep the brain from making cholesterol, which is vital to efficient brain function.
"If you deprive cholesterol from the brain, then you directly affect the machinery that triggers the release of neurotransmitters," said Shin. "Neurotransmitters affect the data-processing and memory functions. In other words -- how smart you are and how well you remember things."
Shin's findings will be published in this month's edition of the journal Proceedings of the National Academy of Sciences of the United States of America.
Cholesterol is one of the building blocks of cells and is made in the liver. Low-density lipoprotein (LDL) -- often referred to as bad cholesterol -- is cholesterol in the bloodstream from the liver on the way to cells in the body. High-density lipoprotein (HDL) -- so-called good cholesterol -- is cholesterol being removed from cells. Too much LDL going to cells and not enough being removed can lead to cholesterol deposits and hardening of the cells.
"If you have too much cholesterol, your internal machinery is not going to be able to take away enough cholesterol from the cells," said Shin. "Then cells harden and you can get these deposits."
Cholesterol-reducing statin drugs are helpful because they keep the liver from synthesizing cholesterol so less of the substance is carried to the cells. This lowers LDL cholesterol.
It is the function of reducing the synthesis of cholesterol that Shin's study shows may also harm brain function.
"If you try to lower the cholesterol by taking medicine that is attacking the machinery of cholesterol synthesis in the liver, that medicine goes to the brain too. And then it reduces the synthesis of cholesterol which is necessary in the brain," said Shin.
In his experiments, Shin tested the activity of the neurotransmitter-release machinery from brain cells without cholesterol present and measured how well the machinery functioned. He then included cholesterol in the system and again measured the protein function. Cholesterol increased protein function by five times.
"Our study shows there is a direct link between cholesterol and the neurotransmitter release," said Shin. "And we know exactly the molecular mechanics of what happens in the cells. Cholesterol changes the shape of the protein to stimulate thinking and memory."
While reducing the cholesterol in the brain may make you have less memory and cognitive skills, more cholesterol in the blood does not make people smarter. Because cholesterol in the blood cannot get across the blood brain barrier, there is no connection to the amount of cholesterol a person eats and brain function.
Shin says that for many people taking cholesterol-lowering statins can be very healthful and they should listen to their doctor when taking medication.
Yeon-Kyun Shin, a biophysics professor in the department of biochemistry, biophysics and molecular biology, says the results of his study show that drugs that inhibit the liver from making cholesterol may also keep the brain from making cholesterol, which is vital to efficient brain function.
"If you deprive cholesterol from the brain, then you directly affect the machinery that triggers the release of neurotransmitters," said Shin. "Neurotransmitters affect the data-processing and memory functions. In other words -- how smart you are and how well you remember things."
Shin's findings will be published in this month's edition of the journal Proceedings of the National Academy of Sciences of the United States of America.
Cholesterol is one of the building blocks of cells and is made in the liver. Low-density lipoprotein (LDL) -- often referred to as bad cholesterol -- is cholesterol in the bloodstream from the liver on the way to cells in the body. High-density lipoprotein (HDL) -- so-called good cholesterol -- is cholesterol being removed from cells. Too much LDL going to cells and not enough being removed can lead to cholesterol deposits and hardening of the cells.
"If you have too much cholesterol, your internal machinery is not going to be able to take away enough cholesterol from the cells," said Shin. "Then cells harden and you can get these deposits."
Cholesterol-reducing statin drugs are helpful because they keep the liver from synthesizing cholesterol so less of the substance is carried to the cells. This lowers LDL cholesterol.
It is the function of reducing the synthesis of cholesterol that Shin's study shows may also harm brain function.
"If you try to lower the cholesterol by taking medicine that is attacking the machinery of cholesterol synthesis in the liver, that medicine goes to the brain too. And then it reduces the synthesis of cholesterol which is necessary in the brain," said Shin.
In his experiments, Shin tested the activity of the neurotransmitter-release machinery from brain cells without cholesterol present and measured how well the machinery functioned. He then included cholesterol in the system and again measured the protein function. Cholesterol increased protein function by five times.
"Our study shows there is a direct link between cholesterol and the neurotransmitter release," said Shin. "And we know exactly the molecular mechanics of what happens in the cells. Cholesterol changes the shape of the protein to stimulate thinking and memory."
While reducing the cholesterol in the brain may make you have less memory and cognitive skills, more cholesterol in the blood does not make people smarter. Because cholesterol in the blood cannot get across the blood brain barrier, there is no connection to the amount of cholesterol a person eats and brain function.
Shin says that for many people taking cholesterol-lowering statins can be very healthful and they should listen to their doctor when taking medication.
понедельник, 25 июля 2011 г.
Blueberries Contain Chemical That May Help Prevent Colon Cancer
A compound found in blueberries shows promise of preventing colon cancer in animals, according to a joint study by scientists at Rutgers University and the U.S. Department of Agriculture. The compound, pterostilbene, is a potent antioxidant that could be developed into a pill with the potential for fewer side effects than some commercial drugs that are currently used to prevent the disease. Colon cancer is considered the second leading cause of cancer death in the United States, the researchers say.
While recent studies have identified a growing number of antioxidants in fruits, vegetables and whole grains that show potential for fighting colon cancer, this is believed to be the first study to demonstrate the cancer-fighting potential of pterostilbene against the disease, the scientists say. Their findings were described at the 233rd national meeting of the American Chemical Society. March is National Colorectal Cancer Awareness Month.
"This study underscores the need to include more berries in the diet, especially blueberries," says study leader Bandaru Reddy, Ph.D., a professor in the Department of Chemical Biology at Rutgers in Piscataway, N.J. Although the blueberry compound won't cure colon cancer, it represents a potential new and attractive strategy for preventing the disease naturally, says Reddy, a leading expert on nutritional factors that influence colon cancer development.
Along with scientists Nanjoo Suh, also of Rutgers, and Agnes Rimando of the USDA's Agricultural Research Service (ARS), Reddy and his associates conducted a small pilot study to determine the effect of pterostilbene on colon cancer. The study included 18 rats that were given a compound (azoxymethane) to induce colon cancer in a manner similar to human colon cancer development. Nine of the animals were then placed on a balanced daily diet, while the other nine were given the same diet supplemented with pterostilbene (at a level of 40 parts per million).
At the end of an eight-week study period, the rats that were fed pterostilbene showed 57 percent fewer pre-cancerous lesions in their colon in comparison to the control group, Reddy and his associates say. Pterostilbene also reduced colonic cell proliferation and inhibited certain genes involved in inflammation, both of which are considered colon cancer risk factors, the researchers say.
Although researchers still do not know the exact cause of colon cancer, the disease has been linked to a high intake of saturated fats and calories, particularly in Western diets. Pterostilbene may be able to reverse this process, possibly by lowering lipids, Reddy says. He cites a recent study by co-author Agnes Rimando, a research chemist at the USDA-ARS, who demonstrated in cell and animal studies that pterostilbene is capable of lowering cholesterol levels. In a related paper also presented at the ACS national meeting, Rimando demonstrated that blueberries, particularly their skins, can lower cholesterol when fed to animals (see AGFD 038 reference below). More studies on the mechanism of action of pterostilbene are needed, the researchers note.
Reddy recently demonstrated that certain COX-2 inhibitors, anti-inflammatory drugs that are used for pain and arthritis, were capable of preventing colon cancer in animals. But studies by others have shown that COX-2 inhibitors also can increase the risk of heart attacks and strokes when used in high doses. Combining pterostilbene with these COX-2 drugs could allow them to be used in lower doses, reducing their risk of adverse side effects, Reddy says. More studies are needed to determine the compound's efficacy and potential for toxicity, he notes.
Pterostilbene is an antioxidant that is similar to resveratrol, an antioxidant identified in grapes and red wine that also is recognized for its anticancer properties. Pterostilbene also is found in grapes, but it is more abundant in blueberries, the researchers say.
In studies by other researchers, blueberries also have shown promise for protecting against memory loss and heart disease. In general, a diet rich in fruits, vegetables and grain is recommended by health experts for the prevention of colon cancer. Funding for this study was provided by the National Cancer Institute.
Mark T. Sampson
The American Chemical Society - the world's largest scientific society - is a nonprofit organization chartered by the U.S. Congress and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
The paper on this research, AGFD 009, was presented during the symposium, "Natural Products, Diets and Cancer Prevention."
Bandaru S. Reddy, D.V.M., Ph.D., is a research professor in the Department of Chemical Biology, Susan Lehman Cullman Laboratory for Cancer Research, Rutgers University, in Piscataway, N.J.
Related Paper:
Blueberry skins can lower cholesterol in animals - Hamsters with high cholesterol levels that were fed a diet that includes blueberry skins showed significantly lower levels of cholesterol and triglycerides compared to a control group of hamsters that were not fed blueberry skins, according to a joint study by USDA researchers. Pterostilbene, an antioxidant previously shown to lower cholesterol levels in cell and animal studies, is believed to be one of the active ingredients in the blueberry skins, they say. (AGFD 038)
Contact:
Charmayne Marsh
Michael Bernstein
American Chemical Society
While recent studies have identified a growing number of antioxidants in fruits, vegetables and whole grains that show potential for fighting colon cancer, this is believed to be the first study to demonstrate the cancer-fighting potential of pterostilbene against the disease, the scientists say. Their findings were described at the 233rd national meeting of the American Chemical Society. March is National Colorectal Cancer Awareness Month.
"This study underscores the need to include more berries in the diet, especially blueberries," says study leader Bandaru Reddy, Ph.D., a professor in the Department of Chemical Biology at Rutgers in Piscataway, N.J. Although the blueberry compound won't cure colon cancer, it represents a potential new and attractive strategy for preventing the disease naturally, says Reddy, a leading expert on nutritional factors that influence colon cancer development.
Along with scientists Nanjoo Suh, also of Rutgers, and Agnes Rimando of the USDA's Agricultural Research Service (ARS), Reddy and his associates conducted a small pilot study to determine the effect of pterostilbene on colon cancer. The study included 18 rats that were given a compound (azoxymethane) to induce colon cancer in a manner similar to human colon cancer development. Nine of the animals were then placed on a balanced daily diet, while the other nine were given the same diet supplemented with pterostilbene (at a level of 40 parts per million).
At the end of an eight-week study period, the rats that were fed pterostilbene showed 57 percent fewer pre-cancerous lesions in their colon in comparison to the control group, Reddy and his associates say. Pterostilbene also reduced colonic cell proliferation and inhibited certain genes involved in inflammation, both of which are considered colon cancer risk factors, the researchers say.
Although researchers still do not know the exact cause of colon cancer, the disease has been linked to a high intake of saturated fats and calories, particularly in Western diets. Pterostilbene may be able to reverse this process, possibly by lowering lipids, Reddy says. He cites a recent study by co-author Agnes Rimando, a research chemist at the USDA-ARS, who demonstrated in cell and animal studies that pterostilbene is capable of lowering cholesterol levels. In a related paper also presented at the ACS national meeting, Rimando demonstrated that blueberries, particularly their skins, can lower cholesterol when fed to animals (see AGFD 038 reference below). More studies on the mechanism of action of pterostilbene are needed, the researchers note.
Reddy recently demonstrated that certain COX-2 inhibitors, anti-inflammatory drugs that are used for pain and arthritis, were capable of preventing colon cancer in animals. But studies by others have shown that COX-2 inhibitors also can increase the risk of heart attacks and strokes when used in high doses. Combining pterostilbene with these COX-2 drugs could allow them to be used in lower doses, reducing their risk of adverse side effects, Reddy says. More studies are needed to determine the compound's efficacy and potential for toxicity, he notes.
Pterostilbene is an antioxidant that is similar to resveratrol, an antioxidant identified in grapes and red wine that also is recognized for its anticancer properties. Pterostilbene also is found in grapes, but it is more abundant in blueberries, the researchers say.
In studies by other researchers, blueberries also have shown promise for protecting against memory loss and heart disease. In general, a diet rich in fruits, vegetables and grain is recommended by health experts for the prevention of colon cancer. Funding for this study was provided by the National Cancer Institute.
Mark T. Sampson
The American Chemical Society - the world's largest scientific society - is a nonprofit organization chartered by the U.S. Congress and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
The paper on this research, AGFD 009, was presented during the symposium, "Natural Products, Diets and Cancer Prevention."
Bandaru S. Reddy, D.V.M., Ph.D., is a research professor in the Department of Chemical Biology, Susan Lehman Cullman Laboratory for Cancer Research, Rutgers University, in Piscataway, N.J.
Related Paper:
Blueberry skins can lower cholesterol in animals - Hamsters with high cholesterol levels that were fed a diet that includes blueberry skins showed significantly lower levels of cholesterol and triglycerides compared to a control group of hamsters that were not fed blueberry skins, according to a joint study by USDA researchers. Pterostilbene, an antioxidant previously shown to lower cholesterol levels in cell and animal studies, is believed to be one of the active ingredients in the blueberry skins, they say. (AGFD 038)
Contact:
Charmayne Marsh
Michael Bernstein
American Chemical Society
пятница, 22 июля 2011 г.
You can prevent Alzheimer's by staying lean, eating fruit and vegetables and exercising
Researchers in a new study say that you can prevent Alzheimer's by staying lean, eating lots of fruit and vegetables and exercising, you will also reduce significantly your risk of developing heart disease. High cholesterol during midlife, as well as high blood pressure will increase your risk of developing Alzheimer's and dementia later in life if you do not do anything about it.
Dr. Marilyn Albert, Alzheimer's Association's Medical and Scientific Council (USA), said "There are a variety of lifestyle factors that people can engage in that will reduce their risk of cognitive decline. The brain is much more plastic than we thought. It has more capacity to renew and regenerate. ... We have to tell people that they need to think about their cognitive health in a way that they typically thought about their physical health…..The pathology of Alzheimer's disease develops over 10 years, possibly longer. People should start as early in life as possible."
A Finnish study found that people who are obese in midlife have twice the risk of developing dementia during old age - the study looked at 1,500 people. The people with high cholesterol and blood pressure had six times the risk.
Women who eat plenty of vegetables during their middle-age years are much less likely to lose their cognitive abilities during their 70s than women who did not eat many vegetables. This study looked at 13,000 women. The study was carried out at the Harvard Medical School, led by Dr. Jae Hee Kang.
According to research carried out at the Karolinska Institute, Sweden, activities which combine mental and physical functions significantly reduce one's chances of developing old age dementia. The researchers stressed that the activities must be combined to provide the best protection.
Dr. Marilyn Albert, Alzheimer's Association's Medical and Scientific Council (USA), said "There are a variety of lifestyle factors that people can engage in that will reduce their risk of cognitive decline. The brain is much more plastic than we thought. It has more capacity to renew and regenerate. ... We have to tell people that they need to think about their cognitive health in a way that they typically thought about their physical health…..The pathology of Alzheimer's disease develops over 10 years, possibly longer. People should start as early in life as possible."
A Finnish study found that people who are obese in midlife have twice the risk of developing dementia during old age - the study looked at 1,500 people. The people with high cholesterol and blood pressure had six times the risk.
Women who eat plenty of vegetables during their middle-age years are much less likely to lose their cognitive abilities during their 70s than women who did not eat many vegetables. This study looked at 13,000 women. The study was carried out at the Harvard Medical School, led by Dr. Jae Hee Kang.
According to research carried out at the Karolinska Institute, Sweden, activities which combine mental and physical functions significantly reduce one's chances of developing old age dementia. The researchers stressed that the activities must be combined to provide the best protection.
Подписаться на:
Сообщения (Atom)